Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease

Haynes, Richard, Lewis, David, Emberson, Joanthan, Reith, Christina, Agodoa, Lawrence, Cass, Alan, Craig, Jonathan C., de Zeeuw, Dick, Feldt-Rasmussen, Bo, Fellstroem, Bengt, Levin, Adeera, Wheeler, David C., Walker, Rob, Herrington, William G., Baigent, Colin and Landray, Martin J. (2014). Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology,25(8):1825-1833.

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 37
Google Scholar Search Google Scholar

IRMA ID 75039815xPUB280
Title Effects of Lowering LDL Cholesterol on Progression of Kidney Disease
Author Haynes, Richard
Lewis, David
Emberson, Joanthan
Reith, Christina
Agodoa, Lawrence
Cass, Alan
Craig, Jonathan C.
de Zeeuw, Dick
Feldt-Rasmussen, Bo
Fellstroem, Bengt
Levin, Adeera
Wheeler, David C.
Walker, Rob
Herrington, William G.
Baigent, Colin
Landray, Martin J.
Journal Name Journal of the American Society of Nephrology
Publication Date 2014
Volume Number 25
Issue Number 8
ISSN 1046-6673   (check CDU catalogue open catalogue search in new window)
Start Page 1825
End Page 1833
Total Pages 9
Place of Publication United States
Publisher American Society of Nephrology
HERDC Category C1 - Journal Article (DIISR)
Abstract Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo. The main prespecified renal outcome was ESRD (defined as the initiation of maintenance dialysis or kidney transplantation). During 4.8 years of follow-up, allocation to simvastatin plus ezetimibe resulted in an average LDL cholesterol difference (SEM) of 0.96 (0.02) mmol/L compared with placebo. There was a nonsignificant 3% reduction in the incidence of ESRD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases with placebo; rate ratio, 0.97; 95% confidence interval [95% CI], 0.89 to 1.05; P=0.41). Similarly, allocation to simvastatin plus ezetimibe had no significant effect on the prespecified tertiary outcomes of ESRD or death (1477 [47.4%] events with treatment versus 1513 [48.3%] events with placebo; rate ratio, 0.97; 95% CI, 0.90 to 1.04; P=0.34) or ESRD or doubling of baseline creatinine (1189 [38.2%] events with treatment versus 1257 [40.2%] events with placebo; rate ratio, 0.93; 95% CI, 0.86 to 1.01; P=0.09). Exploratory analyses also showed no significant effect on the rate of change in eGFR. Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD.
DOI http://dx.doi.org/10.1681/ASN.2013090965   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 164 Abstract Views  -  Detailed Statistics
Created: Wed, 19 Aug 2015, 12:14:20 CST